We used a non-viral gene delivery approach to explore the potential of the plant saporin (SAP) gene as an alternative to the currently employed suicide genes in cancer therapy. Plasmids expressing cytosolic SAP were generated by placing the region encoding the mature plant ribosome-inactivating protein under the control of cytomegalovirus (CMV) or simian virus 40 (SV40) promoters. Their ability to inhibit protein synthesis was first tested in cultured tumor cells co-transfected with a luciferase reporter gene. In particular, SAP expression driven by CMV promoter (pCI-SAP) demonstrated that only 10 ng of plasmid per 1.6 Â 10 4 B16 cells drastically reduced luciferase activity to 18% of that in control cells. Direct intratumoral injection of pCI-SAP complexed with either lipofectamine or N-(2,3-dioleoyloxy-1-propyl) trimethylammonium methyl sulfate (DOTAP) in B16 melanoma-bearing mice resulted in a noteworthy attenuation of tumor growth. This antitumor effect was increased in mice that received repeated intratumoral injections. A SAP catalytic inactive mutant (SAP-KQ) failed to exert any antitumor effect demonstrating that this was specifically owing to the SAP N-glycosidase activity. Our overall data strongly suggest that the gene encoding SAP, owing to its rapid and effective action and its independence from the proliferative state of target cells might become a suitable candidate suicide gene for oncologic applications.
Introduction
Gene therapy has been investigated as an alternative or complementary strategy to overcome the limitations of conventional anticancer therapy approaches. Rather than in correcting specific genetic defects within cancer cells, one current promise of cancer gene therapy stands in eradicating the tumor by the transfer of so-called suicide genes, or by the delivery of immunomodulatory genes that promote tumor rejection by the activation of the immune system. 1, 2 Additional gene therapy strategies are designed to target tumor stroma, aimed in particular at inhibiting neoangiogenesis or destroying tumoral vascular supply. 3, 4 Strategies based on suicide genes that have been explored for the treatment of various cancer types mostly rely on gene-directed enzyme prodrug therapy. The gene encoding an enzyme can be delivered to tumor cells, followed by the administration of a prodrug, which is then converted locally into a cytotoxin by this specific enzymatic activity. Several such systems already underwent clinical trials: Herpes simplex virus thymidine kinase/gancyclovir, bacterial cytosine deaminase/5-fluorocytosine, bacterial nitroreductase/CB1954 and cytochrome P450/cyclophosphamide. 5 As an alternative, recently it has been suggested that some bacterial or plant toxins such as diphtheria toxin 6, 7 Pseudomonas aeruginosa exotoxin A 8, 9 or ricin 9,10 would be suitable candidates for cancer gene therapies. In contrast to other suicide genes that act by disrupting DNA synthesis, thus targeting only rapidly dividing cells, these toxins are potent inhibitors of protein synthesis, which acts in a cell cycle-independent manner, killing both quiescent and rapidly dividing tumor cells. Thus, such toxins can be an effective therapy for aggressively growing tumors as well as for other tumor types that grow more slowly.
Another plant toxin potentially interesting for cancer gene therapy approaches is saporin (SAP), a monomeric plant ribosome-inactivating protein (RIP) accumulated in seeds and leaves of the soapwort, Saponaria officinalis.
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SAP depurinates the 23/25/28 S ribosomal RNA, thus blocking peptidyl-transfer RNA translocation during protein synthesis 12 and leading to an irreversible inactivation of ribosomes. Moreover, a number of studies have demonstrated specific DNAse-like activity of RIPs, including SAP, as evidenced by DNA fragmentation. 13, 14 Such DNA damage, characterized by micronuclei formation and the appearance of cytosolic oligonucleosomes, might play a role in the induction of apoptosis upon cell exposure to the toxin and contribute to target cell killing.
SAP is a single-chain (type I) RIP and lacks the membrane binding domain found in the prototype ricin AB. Three-dimensional structure of the catalytic ricin A chain (RTA) is superimposable with that of SAP despite the fact that their amino-acid identity is lower than 25%. RTA has a very low lysine content and a slightly acidic pI whereas 10% of the amino acids in SAP are lysine residues, which confer also an extremely high pI (almost 10) to this polypeptide. In addition, SAP can be internalized through members of the low-density lipoprotein-related receptor family 15, 16 and has a much higher cell-free RIP activity, compared to RTA. 15, 16 Acting catalytically, SAP has very high intrinsic activity as it has been established that only a few molecules of toxin reaching the cytosolic compartment are sufficient to inhibit protein synthesis and cause cell death. 17 Seed-extracted SAP has been widely used to develop mouse models selectively impaired in central nervous system functions. 11 and in anticancer therapy, to construct immunotoxins or ligand toxins [18] [19] [20] [21] and SAP complementary DNA (cDNA) has been used for expressing targeted recombinant chimeras. 17, [22] [23] [24] [25] When a SAP-based secretory chimera was expressed in Xenopus laevis oocytes, total inhibition of cellular protein synthesis was observed that could be restored only by supplementing neutralizing anti-SAP antibodies into the oocyte cytosol, 26 indicating that, although almost all of the chimera was secreted, the few molecules escaping from the secretory pathway were sufficient to inactivate protein synthesis in the host cells.
Therefore, we decided to investigate the potential of the SAP native gene in cancer gene therapy approaches. In this study, we report that we developed suitable SAP cDNA constructs and tested them both in vitro and in vivo for efficient intratumoral cell killing. To avoid the side effects associated to viral vectors, we used cationic lipids, lipofectamine and N-(2,3-dioleoyloxy-1-propyl) trimethylammonium methyl sulfate (DOTAP), to deliver SAP cDNA to rapidly growing murine melanomas. Despite the poor delivery efficiency associated with non-viral systems, 27 we report here that SAP expression was very effective in retarding tumor growth.
Materials and methods

Cells and reagents
The B16F1 murine melanoma cell line was obtained from American Type Culture Collection (ATCC) (Manassas, VA) and maintained in Rosewell Park Memorial Institute 1640, supplemented with 5% fetal calf serum (FCS), 2 mM L-glutammine, 100 U/ml penicillin, 100 mg/ml streptomycin, 0.25 mg/ml amphotericin. The African green monkey kidney Vero cell line was from ATCC and was grown in high-glucose Dulbecco's Modified Eagle's Medium supplemented with 5% of FCS, 2 mM L-glutammine, 100 U/ ml penicillin, 100 mg/ml streptomycin. FCS and culture media were from Gibco BRL (Milano, Italy). The pCMVLuc plasmid and Luciferase Kit were purchased from Promega (Promega-Italia, Milano, Italy). All restriction enzymes used were from New England Biolabs (Cellbio, Milano, Italy). The other chemicals were purchased from Sigma (Sigma-Aldrich s.r.l., Milano, Italy), unless reported otherwise.
Construction of SAP-encoding plasmids
The pCI-SAP plasmid was prepared by inserting the sequence encoding mature SAP-3 16 into the pCISfiRsrT vector. 28 This vector has the pCI plasmid backbone (Promega), featuring a cytomegalovirus (CMV) promoter, an artificial intron and splice site, a multiple cloning site and a transcription terminator placed downstream the polyadenylation signal for improved transcription efficiency. The pSfiSV19-SAP plasmid was prepared by subcloning the SAP sequence into the pSfiSV19 under the control of the early simian virus 40 (SV40) promoter. 29 The SAP encoding sequence was obtained from the pET-11d-SAP3 plasmid 16 digested with NcoI and EcoRI; protruding ends were filled in with Klenow DNA polymerase. The SAP fragment was then ligated into SmaI-linearized and dephosphorylated pCIsfiRsrT and pSfiSV19 vectors.
The pCI-SAPKQ construct was prepared by in vitro oligonucleotide mismatch site directed mutagenesis on the pCI-SAP plasmid template, using Pfu Turbo polymerase (Promega-Italia, Milano, Italy). The oligonucleotides used were: forward 5 0 CT ATT CAA ATG ACA GCT AAG GTA GCA CAG TTT AGG TAC ATT C 3 0 ; reverse 5 0 GAA TGT ACC TAA ACT GTG CTA CCT TAG CTG TCA TTT GAA TAG 3 0 (mutated nucleotides are shown in bold). In this way two mutations were inserted: 176 Glu to Lys and 179 Arg to Gln. Polymerase chain reaction conditions were: hot start at 941C 1 min, followed by 20 cycles 951C 1 min, 551C 30 s, 681C 10 min. The template was digested with DpnI.
pCIsfiRsrT or pSfiSV19 vectors were used as control plasmids in transfection experiments.
Large scale preparations of purified DNA for in vivo experiments were performed using EndoFree Plasmid Giga Kit (Qiagen, Milano, Italy) according to the manufacture's instructions. All plasmid preparations were tested for endotoxin contamination using the Limulus Amebocyte Lysate assay (Bio-Whittaker, Verviers, Belgium). The endotoxin content was less than 0.01 EU/mg of plasmid DNA.
Transfection assays
Cells (1.6 Â 10 4 )/well were plated in a 48-multiwell plate and incubated for 24 h. Cells were then co-transfected with increasing amounts of pSfiSV19-SAP or pCI-SAP, mixed with complementary decreasing amounts of control Saporin non-viral gene expression in B16 melanomas N Zarovni et al vector and with a constant amount of luciferase encoding plasmid (0.4 mg/well). Plasmid DNA (total 0.8 mg/well) and 100 mM polyethylenimine (PEI) 30 were diluted separately in 0.9% sodium chloride solution and then mixed at the amino to phosphate group ratio (N/P) 9:1. After 20 min, the mixture was added to the cells and incubated for 4 h; the supernatant was then removed and replaced with fresh medium.
Twenty-four hours after transfection, cells were washed once with phosphate-buffered saline (PBS), resuspended in 100 ml/well of lysis buffer (125 mM Tris-HCl (pH 8), 10 mM dithiothreitol, 10 mM ethylenediaminetetraacetic acid (pH 8), 50% Glycerol, 5% Triton X-100) and incubated at 41C for 30 min with shaking. Luciferase activity in cell lysates was measured using the Luciferase Assay System (Promega). Results were normalized relative to protein content, measured using the Bradford protein assay method. Protein concentrations were calculated from a bovine serum albumin standard curve and luciferase activity was expressed in relative light units per microgram of protein and presented as a percent of that estimated in the control transfections using only luciferase pCMVLuc, as in. 31 Results of representative experiments are expressed as means7s.d. of at least three wells per condition/sample. Statistical significance was assessed using unpaired-sample Student's t-test (GraphPad Prism software). All data were considered statistically significant at Po0.05. Analysis of variance (ANOVA) one-way post-test statistical analysis (GraphPad Prism software) was also used to confirm the statistical significance of the data.
MTT staining B16F1 melanoma cells were seeded and transfected as described above. After 24 h of incubation at 371C and 5% CO 2 , 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (5 mg/ml in PBS) was added (10 ml/well) and the plate was placed at 371C and 5% CO 2 . After 3 h, supernatants were removed and 200 ml/well of dimethylsulfoxide were added to dissolve the crystals formed. Cell viability was assessed by reading the absorbance at 570 nm.
In vivo studies All studies on animal models were approved by the Ethical Committee of the San Raffaele H Scientific Institute and performed according to its guidelines. C57BL/6 female mice (Charles River Laboratories, Calco, Italy) weighing 18-20 g were injected subcutaneously with 5 Â 10 4 B16F1 cells in the left flank. About 8-10 days after inoculation, when mice developed a 5 mm diameter tumor, selected groups of animals received a direct intratumoral injection of pCI-SAP or control plasmid (50 mg per animal) complexed with lipofectamine or DOTAP dissolved in 20 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulphonic acid at ratio (N/P) 1:6.7 and 1:4.8, respectively. The effect of single or repeated administrations (2 and 5 days after the first injection) on tumor growth was monitored with callipers. Animals were killed before the tumor reached a diameter of 1.5 cm.
Tumor volume is presented as mean7s.e. of at least five animals per group. Statistical significance was assessed using unpaired-sample Student's t-test. All data were considered statistically significant at Po0.05. ANOVA one-way post-test statistical analysis (GraphPad Prism software) was also used when three groups could be compared, confirming the statistical significance of our in vivo data.
Results
Expression of SAP-encoding constructs in vitro
The possibility of using SAP cDNA as a novel suicide gene in cancer gene therapy was first investigated in vitro, by assessing the effects of two different SAP-encoding constructs, before testing the efficacy of the SAP gene in killing B16 tumor cells in vivo. To achieve this goal, we engineered the mature SAP coding sequence-3 16 into the in vitro amplification mammalian expression vectors 28, 29 to allow the cytosolic expression of SAP under either the CMV or the SV40 promoter, generating respectively pCI-SAP and pSfiSV19-SAP constructs. This would allow toxin expression directly in the same compartment where the target ribosomes are located. Recombinant SAP, when expressed and purified from E.coli, was previously shown to be extremely active both in cell-free translation systems, derived from rabbit reticulocytes 16 and in cell killing assays. 31 To examine SAP-encoding constructs activity, transient co-transfection experiments were performed with increasing amounts of either pCI-SAP or pSfiSV19-SAP and a fixed amount of the luciferase reporter gene. Either Vero cells, derived from African green monkey kidney epithelium, a well characterized model cell line to study toxin delivery [32] [33] [34] or B16-F1 cells, a subclone of an aggressive mouse melanoma that is widely used in antitumor screening procedures, were transfected and the cell lysates assayed for luciferase expression. The results are expressed as a percentage of the luciferase activity estimated in control transfections using only luciferase cDNA. Figure 1 shows that the luciferase relative activity is progressively inhibited when increasing amounts of SAPencoding plasmid are used during transfection, reflecting a total protein synthesis inhibition in the transfected cells.
Both constructs displayed a very high activity ( Figure 1 ) with an effect on protein synthesis found to be dependent on the specific promoter driving SAP expression and on the cell type examined. SAP expression driven by the CMV promoter was apparently much higher than the one driven by the SV40 promoter. The activity of the pSfiSV19-SAP construct was similar in B16 and Vero cells, showing a 70% reduction of luciferase expression following transfection with the lowest concentration of SAP plasmid (100 ng). Conversely, the effects by the CMV promoter-driven construct exceeded by 15-to 700-folds that of pSfiSV19-SAP. Notably, the effect of pCI-SAP transfections were particularly prominent in B16 cells. Therefore, we titrated the minimal amount of SAP cDNA needed to inhibit luciferase expression/activity; the experiments revealed that as few as 10 ng of the plasmid per 1.6 Â 10 4 B16 cells were sufficient to drastically reduce the luciferase activity to 18% with respect to controltreated cells (Figure 2a) .
These transfection assays indicate that melanoma cells are extremely sensitive to SAP action, showing luciferase synthesis inhibition, even when minute amounts of SAPencoding construct were used. The co-transfection method has proven to be very useful in evaluating the effects of SAP cDNA delivery as it is not limited by cell transfection efficiency as classical cytotoxicity assays. Cytotoxicity observed by MTT staining of cells treated with increasing amount of SAP encoding plasmids 24 h after transfection ranged from 42 to 56% only (Figure 2b) . These results are consistent with the expected efficiency of PEI-mediated transfections that we previously estimated to be around 50% (data not shown).
As we need a promoter that induces a burst of SAP expression sufficient for the rapid killing of cancer cells, and the CMV promoter proved to be more effective than the SV40 one for expression of cytosolic SAP cDNA in the melanoma cell line, we next tested the effect of pCI-SAP delivery on tumor growth in vivo.
Injection of a SAP-encoding construct induces a marked antitumor effect in B16 melanoma-bearing mice The potential of pCI-SAP to promote tumor cell killing in vivo was evaluated by direct injection of the plasmid complexed with either DOTAP or lipofectamine in B16F1 subcutaneous tumors in C57 mice. These two cationic lipids were selected as the most efficient ones in our hands for delivering the luciferase reporter gene to the tumor tissue upon direct intratumoral administration of DNAlipoplexes ( Figure 3) . A single administration of 50 mg of pCI-SAP 10 days after tumor cell implantation, when tumors reached a diameter of about 5 mm, was sufficient to significantly slow down the rate of tumor growth (Figure 4a ). To improve the efficiency and duration of the suicide gene expression, repeated administrations of the SAP gene were performed. The antitumor effect was, as expected, more evident in mice that received repeated intratumoral injections of pCI-SAP/DOTAP complexes at days 2 and 5 from the first treatment (Figure 4c ). In this case we observed an 8-day delay of tumor growth in pCI-SAPtreated animals with respect to untreated animals and 6 days with respect to those that received control injections. Most, but not all, of the mice treated with pCI-SAP developed ulcers like lesions at the injection site. Apart from this intriguing observation, the SAP antitumor effect was accompanied by no evidence of systemic toxicity (i.e. animal death, loss of body weight, other tissue damage or changes in behavior or aspect).
These results suggest that intratumoral administration of pCI-SAP may induce local production of toxin that is able to significantly attenuate the growth of an aggressive tumor such as B16 melanoma.
The catalytic activity of SAP is mainly responsible for the observed antitumor effects To confirm that the observed antitumor effect relies on the expression of the SAP gene within tumor cells and is Results are presented as mean7s.e. of five animals per group.^Po0.05 relative to untreated; *Po0.05 relative to control plasmid;^^Po0.01 relative to untreated; **Po0.01 relative to control plasmid.
Saporin non-viral gene expression in B16 melanomas N Zarovni et al not only owing to an unspecific protein production, we repeated the experiments using a SAP catalytic active site mutant (SAP-KQ), which has a significantly reduced RIP activity (Fabbrini and Ceriotti, unpublished results). Co-transfection assays performed in B16 cells comparing pCI-SAP and pCI-SAP-KQ plasmids activity (Figure 5a ) confirmed that pCI-SAP drastically reduced luciferase activity in transfected cells in a dose-dependent manner, whereas no dose-response could be detected when pCI-SAP-KQ plasmid was used.
Accordingly, when the wild-type and mutant genes were complexed with DOTAP and injected into B16 tumors, pCI-SAP/DOTAP administration markedly affected tumor growth, whereas pCI-SAP-KQ/DOTAP failed to exert a significant antitumor effect, showing only a modest delay in tumor growth, comparable to that observed in control-treated animals (Figure 5b) .
We conclude that SAP-specific catalytic activity is responsible for the observed cell killing effects, therefore excluding that this effect can be merely owing to the exogenous expression of a heterologous plant protein.
Discussion
In this study, we investigated the potential use of the plant toxin SAP cDNA as a suicide gene in cancer gene therapy approaches. Toxins have been widely used in anticancer therapy as components of immunotoxins or recombinant chimeras in which the catalytic moieties (endowed by poor selectivity and permeability) were linked to tumortargeting ligands or antibodies that mediate their binding and internalization by malignant cells. 36 Such protein toxins include bacterial toxins like Pseudomonas aeruginosa exotoxin A and diphtheria toxin 37 or plant toxins like ricin and SAP. 38 In particular, native seed extracted SAP has been conjugated to specific monoclonal antibodies (anti-CD19, -CD22, and -CD38) producing a cocktail of immunotoxins that resulted curative in animal models of B-cell lymphoma. 21 Also SAP-based chimeric toxins targeting either receptors highly expressed on the surface of cancer cells like those for basic fibroblast growth factor (bFGF) or for human urokinase or specific prostate antigen expressing cells exerted high specific cytotoxic activity. 17, 19, 25, 26 However, the cytotoxicity of all these compounds depends not only on tumor accessibility and penetration but also on an efficient internalization, intracellular sorting and release of catalytically active toxin domains into the cytoplasm. Another common drawback of such an approach is the resistance acquired by cancer cells caused by either loss or downregulation of specific receptors by autocrine ligands which, thus, reduce binding and internalization of the recombinant toxin. The use of appropriate DNA constructs encoding toxins that can be directly expressed in the cytosol of the target cells [6] [7] [8] [9] [10] may overcome such problems. Cell killing activity of a SAP gene in vitro resulted comparable to that of the Herpes simplex gene encoding thymidine kinase followed by ganciclovir treatment. 40 SAP is almost four to five times more potent than plant ricin A chain over rabbit retyculocyte ribosomes showing IC 50 in the picomolar range.
16, 31 We demonstrate here that SAP cDNA expression is highly toxic both in vitro and in vivo: as few as 10 ng of pCI-SAP per 1.6 Â 10 4 melanoma cells were sufficient to drastically inhibit protein synthesis and consequently to kill the transfected cells. In addition, in the B16 mouse melanoma model, direct intratumoral injection of pCI-SAP plasmid significantly attenuated tumor growth, with an effect that was clearly improved upon repeated administrations. The antitumor activity observed was specifically owing to the intrinsic activity of SAP and not to simple expression of a heterologous plant protein, as plasmid encoding a catalytic inactive mutant SAP-KQ, generated by mutation of two key active site residues (E176K and R179Q in mature SAP), could neither inhibit luciferase expression nor delay tumor growth in mice.
Classical suicide genes, like herpes simplex virus thymidine kinase, act by disrupting DNA synthesis and this limit their action to tumors characterized by rapidly dividing cells. Toxin genes act in a cell cycle independent way, so that they can target quiescent and rapidly dividing tumor cells. This property makes them suited both to contrast aggressively growing tumors (e.g., melanoma) and for other tumor types that grow more slowly (e.g., prostate tumors).
SAP has been shown to induce programmed cell death, presumably as a consequence of protein synthesis inhibition 41, 42 and may have a direct DNA fragmentation activity.
14 Similarly to other RIPs, one molecule of SAP reaching the cytosol is thought to be sufficient for cell killing. 17 Despite a marked decrease in cell number upon transfection with SAP cDNA, no SAP polypeptide could be detected using antiSAP antibodies, as previously reported also for a SAP mammalian codon optimized gene transfected via bFGF receptors. 40 This suggests that a brief and even low expression of the SAP native gene (below biochemical detection) is sufficient to kill virtually each transfected cell, a desirable end point of a suicide gene therapy.
Cytosolic expression of SAP ensures that it rapidly and directly targets intracellular ribosomes. Although SAP expression would also inhibit its own translation, this does not seem to compromise its efficacy, given that picomolar amounts of toxin are sufficient to inhibit cellular protein synthesis.
In contrast, the concentrations of SAP requested for cell killing following internalization are typically in the micromolar-nanomolar range depending on the cell type. 31 As we could not detect SAP polypeptides in cell cultures upon transfection, we also do not expect that SAP released from dying cells would reach a sufficient amount to allow efficient internalization by the neighboring cells. Therefore, we assume that the SAP toxicity is confined to the transfected cells.
However, in addition to the marked antitumor effect following local gene delivery in vivo, we did observe some ulcer-like lesions at the tumor/injection site. This could possibly be due to some local inflammatory/immune reaction. Although toxins themselves might be highly immunogenic molecules or may elicit a vascular leak syndrome, 43 we did not observe such lesions when injecting mutated SAP-KQ complexes. We therefore hypothesize that such a response could be directed to some components of the intoxicated cells. Further investigation is needed to establish whether SAP action might be potentiated by immunomodulatory effects. An immunomediated bystander effect was suggested in glioblastoma treated by retrovirus expressing the ricin toxic A chain (RTA) gene, where the rejection of tumors was more efficient in the brain of immunocompetent animals than in severe-combined immunodeficient mice. 9 Working at the DNA level avoids costly and timeconsuming production and purification of the recombinant chimeric proteins, whereas allowing direct screening of a wide variety of DNA constructs, for example, employing diverse promoters and transcription regulatory elements, as well as exploring different delivery modes. 44 In the case of systemic delivery, to prevent detrimental expression of toxin in inappropriate tissues, SAP constructs could easily be improved with tissue and/or tumorspecific promoters. 7, 9, [45] [46] [47] [48] [49] In addition, pharmacologically controlled gene expression could be ensured using inducible promoters such as the Tet-on system, which exhibits the best features for applications in patients because it permits rapid gene induction/silencing switch in vivo in a dose-dependent manner and its inducer doxycycline is widely used as an antibiotic and well tolerated in humans (Zabala et al. 50 and references therein).
To test the activity of the native SAP gene in vivo we employed direct intratumoral injection of plasmid DNA complexed with cationic lipids in an aggressive melanoma model. Such an approach proved to be simple, reproducible and less toxic and immunogenic compared to viral delivery systems. Besides, low and transient transgene expression, generally considered a limitation in non-viral gene therapy, does not compromise SAP efficiency, owing to its high intrinsic activity and rapid mode of action.
Non-viral vectors are increasingly being used as an alternative to viral vectors and photochemical internalization of non-viral vectors has been reported to yield high gene transfer efficiency. 51 The direct delivery approach in the context of either viral or non-viral vectors is in general applicable to accessible solid tumors, thus limiting the field of action to a few malignancies, for example, melanoma, head and neck tumors, mesothelioma and so on. However, some of these malignancies are resistant to conventional therapies, and gene therapy trials are warranted, to delineate new potential treatments. SAP-mediated gene therapy can thus contribute to eradicate tumor mass in combination with surgery or classical radio-or chemotherapy.
Overall, we conclude that the features of the SAP gene, such as its rapid and efficient action, the independence from proliferative state of the cell, the fact that no sustained gene expression is required for its efficacy, as well as low leakage of the protein released from intoxicated cells make it a very appealing candidate as a suicide gene for oncologic applications.
